Risk factors for the in-hospital mortality of CRRT-therapy patients with cardiac surgery-associated AKI: a single-center clinical study in China

Yun Jiang1 · Jianle Chen1 · Yamin Yu2 · Fan Yang3 · Mohsin Hamza4 · Ping Zou4 · Ailing Wen4 · Huihui Wu4 · Yide Zhang5

Received: 22 December 2020 / Accepted: 27 August 2022 / Published online: 9 September 2022
© The Author(s) 2022

Abstract
Objective We retrospectively analyzed risk factors on in-hospital mortality in CRRT-therapy patients with open cardiac surgery (CS)-induced acute kidney injury (AKI), to provide the clinical basis for predicting and lowering the in-hospital mortality after CS.

Methods 84 CS-AKI patients with CRRT were divided into survival and death groups according to discharge status, and the perioperative data were analyzed with R version 4.0.2.

Results There were significant differences between the two groups, including: urea nitrogen, Sequential Organ Failure Assessment (SOFA) score and vasoactive-inotropic score (VIS) on the first day after operation; VIS just before CRRT; SOFA score and negative balance of blood volume 24 h after CRRT; the incidence rate of bleeding, severe infection and MODS after operation; and the interval between AKI and CRRT. Univariate logistic regression analysis showed that SOFA score and VIS on the first day after operation; VIS just before CRRT; VIS and negative balance of blood volume 24 h after CRRT; the incidence rate of bleeding, infection and multiple organ dysfunction syndrome (MODS) after operation; bootstrap resampling analysis showed that SOFA score and VIS 24 h after CRRT, as well as the incidence of bleeding after operation were the independent risk factors.

Conclusion Maintaining stable hemodynamics and active prevention of bleeding are expected to decrease the in-hospital mortality.

Keywords CS-AKI · CRRT · In-hospital death · Risk factors

Introduction

In recent years, tremendous progress has been made in the field of cardiac surgery. Therefore, the incidence rate of CS-AKI is also on the rise, which not only affects the surgical efficacy and prolongs the ICU stay time, but also increases the in-hospital mortality rate. At present, although CRRT has been recognized as an optimal and effective treatment for CS-AKI [1], but the mortality rate still remains as high as 50% [2].
**Objects and methods**

**Objects**

84 patients in our hospital from January 2013 to August 2021 in cardiothoracic intensive care unit were enrolled. All patients wrote informed consent, and all protocols were approved by our hospital’s institutional review board (IRB number: 2020-K046). Every participant agreed that personal medical information would be legally and reasonably used. Moreover, their privacy will be fully protected. The enrollment criteria included: (1) age over 18 years; (2) coagulation function and other indicators within the normal range; and (3) AKI patients who received CRRT after cardiac surgery. AKI was defined according to the KDIGO criteria [3]: increase in serum creatinine ≥ 0.3 mg/dl within 48 h; or increase in serum creatinine ≥ 1.5 times baseline; or urine volume < 0.5 ml/kg/h for 6 h. The baseline of sCr was defined as the lowest value monitored during hospitalization and follow-up. The exclusion criteria were as follows: (1) pre-existing chronic renal insufficiency; (2) CRRT less than 24 h. CRRT indications included: urine volume and/or serum creatinine values meeting the criteria for AKI diagnosis after cardiac surgery [4], and deterioration of the patient’s condition with sustained oliguria, severe hyperkalemia and acidosis even after intensive intervention, such as diuretics, volume expansion and vasoactive agents. All 84 patients in the study were divided into a survival group and death group according to the hospital discharge status.

**Methods**

Patient’s data were collected: (1) preoperative data: gender, age, body mass index, history of hypertension and diabetes, preoperative LVEF, cardiac function assessment according to NYHA; (2) intraoperative data: extracorporeal circulation time, aortic occlusion time, blood transfusion, lactic acid peak, blood glucose peak; (3) postoperative data: lab test reports for routine blood tests, liver and kidney function, lactic acid level, potassium, SOFA score and VIS [5], which were collected on the first day after surgery, before CRRT and 24 h after CRRT, as well as the state of volume after 24 h of CRRT. Additionally, postoperative hypoxemia, bleeding, infection, low cardiac output syndrome (LCOS), and secondary tracheal intubation, the duration of mechanical ventilation (MV), the interval time between operation and AKI, as well as the interval time from AKI to CRRT were collected in detail. PaO₂ < 60 mmHg was diagnosed as hypoxemia; the bleeding specifically referred to pulmonary, intracranial or gastrointestinal hemorrhage after operation, or necessity for an additional operation to control bleeding after the end of the sternotomy; infection was defined as a new surgical-site infection, positive blood culture, or development of postoperative pneumonia.

**Statistical methods**

Data were analyzed with R version 4.0.2 (Free Software Foundation, Boston, Massachusetts), Shapiro–Wilk tests were conducted to test the distribution of continuous variables. Normally distributed variables were represented as mean ± standard deviation, and skewed distributed variables were represented as median (inter quantile range, IQR). Paired $t$ tests or Wilcoxon signed-rank tests were applied to compare the differences of paired continuous variables. Independent continuous variables were analyzed by Student’s $t$ test or Mann–Whitney $U$ test. Categorical variables were represented as the frequency (percentage) and were analyzed by the chi-square test or fisher exact test. Variables with clinical significance were chosen for univariate logistic analysis. The statistically significant variables ($P < 0.05$) in the univariate logistic analysis were included in the multivariate logistic regression analysis to identify the independent risk factors. The variables mentioned above were further verified by bootstrap resampling analysis. Two-tailed $P < 0.05$ indicated a statistically significant difference.

**Results**

57 were males and 27 females, with an average age of 61.00 ± 13.35 years. There were 60 patients in the survival group, and 24 in the death group; the in-hospital mortality rate was 28.57%. The preoperative data analysis showed there were no statistically significant differences between survival and death group (Table 1).

The intraoperative data analysis including the duration of extracorporeal circulation and aortic occlusion, the blood transfusion volume, intraoperative lactate peak, as well as the incidence rate of patients with a blood glucose peak > 11.1 mmol/L showed no statistically significant differences between two groups (Table 2).

Statistical analysis showed significant differences between the two groups, including the urea nitrogen, SOFA score and VIS on the first day after operation; VIS just before CRRT, SOFA score and negative balance of blood volume 24 h after CRRT, the incidence rate of bleeding, severe infection and MODS after operation time of MV and the interval from AKI to CRRT (Table 3).

The data including SOFA score and VIS, VIS just before CRRT, VIS and negative balance of blood volume 24 h after CRRT, the incidence rate of bleeding, infection and MODS...
after operation and duration of MV analyzed by univariate logistic regression analysis showed statistical significance; however, multivariate logistic regression analysis showed that only VIS 24 h after CRRT and the incidence rate of bleeding after operation were independent risk factors for in-hospital mortality in CS-AKI patients with CRRT (Table 4). Bootstrap resampling analysis further verified that SOFA score 24 h after CRRT was also the independent one (appendix, Supplement Table 1).

Discussion

Cardiorenal syndrome is a clinical vicious cycle that involves both heart and renal dysfunction. This syndrome has high morbidity and mortality [6, 7]. CS-AKI is usually caused independently or interactively by multiple factors, such as inflammation, ischemia and nephrotoxicity. After CS-AKI, the increased volume of systemic circulation and cardiac preload may lead to heart failure, ultimately gives rise to hemodynamic disorder aggravation and perpetuation of this vicious cycle. CRRT is an effective solution which can not only remove inflammatory mediators and metabolic toxins, but also promote hemodynamic stability and maintain the balance of fluid, electrolytes and acids/bases. Many previous researches showed that CRRT was associated with better in-hospital and long-term survival of patients developing AKI after cardiac surgery [8–10]. However, the in-hospital mortality rate remains high, Perez-Valdivieso [11] reported 50% of in-hospital mortality rate, Han [12] reported 60% of mortality rate within 90 days after surgery, our research showed 28.57% of in-hospital mortality rate. It is a big challenge for cardiac surgeons and nephrologists, the potential risk factors are urgently needed to uncover. Many studies have been done and attempted to figure out potential risk factors for the high mortality, including intraoperative transfusion, high lactic acid, low mean arterial pressure, timing of CRRT, positive blood volume post CRRT, duration of MV and post-operation bleeding, different authors held different opinion according to their own studies [13–20].

Our study showed that the urea nitrogen, SOFA score and VIS on the first day after operation, VIS just before CRRT, SOFA score and VIS and negative balance of blood volume 24 h after CRRT, the incidence rate of bleeding, severe infection and MODS after operation, duration of MV might impact the in-hospital mortality rate. Because of small sample, we selected VIS and negative balance of blood volume 24 h after CRRT, complicated bleeding, infection and MODS after operation, as well as duration of MV might impact the in-hospital mortality rate. Because of small sample, we selected VIS and negative balance of blood volume 24 h after CRRT, duration of MV and post-operation bleeding, different authors held different opinion according to their own studies [13–20].

Table 1 Preoperative general information in the survival and death groups

| General Information                  | Survival group (60 cases) | Death group (24 cases) | P     |
|-------------------------------------|--------------------------|------------------------|-------|
| Gender (cases, male %)             | 41 (68)                  | 16 (67)                | 1     |
| Age (year)                         | 62.5 (53.5, 73)          | 63 (54.75, 73.25)      | 0.988 |
| Body weight index (kg/m²)          | 24.74 (23.28, 25.5)      | 24.6 (22.67, 26.1)     | 0.961 |
| Hypertension (cases %)             | 27 (55)                  | 11 (54)                | 1     |
| Diabetes (cases %)                 | 13 (22)                  | 7 (29)                 | 0.656 |
| LVEF, Median (Q1,Q3)               | 0.58 (0.56, 0.64)        | 0.56 (0.5, 0.62)       | 0.098 |
| Class III-IV of NYHA (cases)       | 11 (18)                  | 9 (38)                 | 0.114 |
| Moderate and severe pulmonary hypertension (cases %) | 31 (52) | 13 (54) | 1 |

Table 2 Intraoperative data in the survival and death groups

| Data                                | Survival group (60 cases) | Death group (24 cases) | P     |
|-------------------------------------|--------------------------|------------------------|-------|
| Duration of extracorporeal circulation (min) | 172 (135.75, 229.75) | 159 (134.5, 183) | 0.331 |
| Aortic occlusion time (min)         | 109 (82.5, 131.75)       | 89.5 (79.25, 108.75)  | 0.17  |
| Blood transfusion (ml)              | 400 (200, 900)           | 600 (187.5, 800)      | 0.676 |
| Lactic acid peak (mmol/L)           | 4.1 (3.13, 5.82)         | 5.9 (3.65, 7.4)       | 0.062 |
| Blood sugar peak >11.1 mmol/L (cases %) | 39 (65) | 15 (62) | 1 |
score after CRRT was significantly different between the two groups, the univariate logistic regression analysis did show statistical significance, bootstrap resampling approach further supported the result above, which was consistent with previous studies.

The VIS was originally introduced by Gaies et al. based on Wernovsky formula [5]. Yamazaki [24] showed that VIS could accurately predict mortality after heart surgery. This study coincidently showed that the death group had a significantly higher VIS on the first day after operation, before CRRT and 24 h after CRRT, which is in agreement with a previous report by Yamazaki [24]. Vasoactive drugs can improve cardiac output and contractility, mitigate hypotension, and enhance perfusion of important organs, but these

### Table 3  Postoperative variables in the survival and death groups

| Data                        | Survival group (60 cases) | Death group (24 cases) | P    |
|-----------------------------|--------------------------|------------------------|------|
| **First day after surgery** |                          |                        |      |
| WBC ($\times 10^9/L$)       | 10.95 (9.1, 13.55)       | 12.6 (10.6, 14.2)      | 0.217|
| Platelets ($\times 10^9/L$) | 100.5 (68, 139)          | 96 (52, 151.5)         | 0.744|
| Total bilirubin ($\mumol/L$)| 24.6 (19.8, 35.02)      | 25.45 (14.88, 35.22)   | 0.976|
| Creatinine ($\mumol/L$)     | 152 (122.75, 197.75)     | 172 (110, 228.75)      | 0.847|
| Urea nitrogen (mmol/L)      | 11.6 (10.3, 14.22)       | 8.2 (7.78, 12.65)      | 0.025*|
| Lactate peak (mmol/L)       | 3.1 (2.28, 4.18)         | 4.1 (2.93, 5.43)       | 0.076|
| SOFA score                  | 12 (12, 17.75)           | 17 (15, 21)            | 0.008*|
| VIS                         | 8.25 (5, 13.12)          | 16 (8.5, 24)           | 0.001*|
| **Pre-CRRT**                |                          |                        |      |
| WBC ($\times 10^9/L$)       | 12.65 (10.47, 16.6)      | 11 (8.97, 15.43)       | 0.155|
| Platelets ($\times 10^9/L$) | 93.5 (60, 160.75)        | 94.5 (69.25, 128.5)    | 0.894|
| Total bilirubin ($\mumol/L$)| 22.1 (15.62, 35.6)       | 23.6 (16.58, 34.5)     | 0.736|
| Creatinine ($\mumol/L$)     | 251.99 ± 95.05           | 227 ± 90.39            | 0.265|
| Urea nitrogen (mmol/L)      | 22 (16.3, 29.63)         | 17.8 (10.92, 28.18)    | 0.109|
| Lactic acid (mmol/L)        | 3.35 (2.2, 4.3)          | 3.65 (2.48, 4.95)      | 0.186|
| SOFA score                  | 14 (13, 15)              | 17 (15.5, 19.5)        | 0.054|
| VIS                         | 14.25 (10, 20.62)        | 28 (23.5, 40.12)       | <0.001*|
| K* (mmol/L)                 | 4.4 (4.18, 4.7)          | 4.3 (4.15, 4.8)        | 0.933|
| **24 h post CRRT**          |                          |                        |      |
| WBC ($\times 10^9/L$)       | 13.1 (10.55, 16.55)      | 13.05 (8.4, 17.18)     | 0.699|
| Platelets ($\times 10^9/L$) | 106 (65, 141.25)         | 77 (51, 126)           | 0.434|
| Total bilirubin ($\mumol/L$)| 24.4 (19.92, 31.3)       | 20.75 (15.7, 27.65)    | 0.216|
| Creatinine ($\mumol/L$)     | 150 (107.5, 194)         | 124 (104.5, 160.25)    | 0.198|
| Urea nitrogen (mmol/L)      | 13.9 (10.3, 17.95)       | 11.5 (8.47, 16.78)     | 0.102|
| Lactic acid (mmol/L)        | 1.5 (1.37, 2.2)          | 1.85 (1.5, 2.38)       | 0.076|
| SOFA score                  | 12 (12, 12.75)           | 18 (15, 18.5)          | <0.001*|
| VIS                         | 9.25 (7, 13)             | 29 (15.75, 50.25)      | <0.001*|
| Negative balance of blood volume (cases %) | 47 (78) | 9 (38) | <0.001* |

| Other information           |                          |                        |      |
| Hypoxemia (cases %)         | 30 (50)                  | 18 (75)                | 0.065|
| Bleeding (cases %)          | 8 (13)                   | 13 (54)                | <0.001*|
| Infection (cases %)         | 15 (25)                  | 18 (75)                | 0.001*|
| LCOS (cases %)              | 26 (43)                  | 16 (67)                | 0.091|
| MODS (cases %)              | 21 (35)                  | 21 (88)                | <0.001*|
| Twice tracheal intubation (cases %) | 16 (27) | 12 (50) | 0.073 |
| Duration MV (min)           | 123 (68.12, 228.94)      | 206.12 (106.67, 404.95)| 0.044*|
| Interval time from surgery to AKI (h) | 49.1 (23.4, 74) | 79.45 (33.13, 132.8) | 0.147|
| Interval time from surgery to CRRT (h) | 55.15 (32.05, 86.4) | 80.68 (34.22, 145) | 0.105|
| Interval time from AKI to CRRT (h) | 5.75 (4.25, 8.14) | 8.1 (6.21, 10.3) | 0.035*|

*There is a statistically significant difference
drugs also cause to higher cardiac oxygen consumption and blood redistribution, which can lead to insufficient blood supply to other organs, further exacerbating metabolic acidosis, myocardial ischemic necrosis, liver and kidney dysfunction, and peripheral circulation failure. In this regard, a higher VIS reflecting more severe hemodynamic disorder can be a reasonable clinical marker for assessing the cardiovascular condition after cardiac surgery [25]. CRRT can remove cytokines and prominently lower the dose of vasoactive drugs [26], tapering vasoactive drugs may improve microcirculation, allow aerobic metabolism to be acquired more easily and decrease the production of inflammatory mediators accordingly, and further improve organ function. This study showed that the VIS 24 h after CRRT was an independent risk factor.

The complication of bleeding was reported as an important marker of treatment safety during CRRT [27]. According to this study, complicated bleeding is an independent risk factor for in-hospital death in these patients. The critically complicated events including pulmonary, gastrointestinal, intracranial, or hepatic hemorrhage could lead to relevant organ dysfunction, even trigger MODS and DIC, which undoubtedly contributed to higher mortality. In addition, increased thoracic drainage and bleeding of the gastrointestinal tract and airway can give rise to down titrated anticoagulant doses, or even discontinuation of anticoagulants during CRRT, which can lead to a potential blockage of extracorporeal circulation pipelines and CRRT inefficiency. This result also indicated that effective management and prevention of bleeding can improve the prognosis of these patients.

Previous studies have indicated that hypervolemia increases the mortality rate in patients with CS-AKI [16, 17], and a negative fluid load balance within 3 consecutive days after CRRT may decrease the mortality rate [28]. In this study, the percentage of cases with a negative fluid balance after 24 h of CRRT was significantly different between the two groups (P < 0.001), which also showed statistical significance by univariate logistic regression analysis (OR = 0.166, P = 0.001), but no statistical significance by multivariate logistic regression analysis (P = 0.148). It is possible that 24 h of CRRT may be too short to show significant differences in fluid homeostasis. Additionally, the small number of clinical observations may impact the significance of the statistical results.

There are still no clear guidelines for CRRT in CS-AKI, the optimal time point for the initiation of CRRT remains to be elucidated. Han [12] showed that the timely and effective development of CRRT will significantly reduce the mortality of CS-AKI patients. After AKI occurs following cardiac surgery, if timely intervention is not available, the condition will further deteriorate, and it will be difficult to achieve satisfactory treatment results in the later stage. However, some studies showed that early CRRT strategy was not associated with a lower risk of death in these patients [10, 29]. In this study, there was statistical significance between the survival group and the death group (P = 0.035). However, the interval time from AKI to CRRT was not related to in-hospital mortality by univariate logistic regression analysis (P = 0.05).

Recently, some scholars have suggested that the indications for CRRT should be changed from narrowly defined renal replacement to systemic organ support, and therapeutic principle should be shifted from a conventional remedy for life-threatening conditions to early individualized requirements for fluid management, systemic inflammation elimination and metabolic toxin clearance [30–32]. Finally, results suggest that the AKI to CRRT interval is not an independent risk factor for the in-hospital mortality of CS-AKI patients.

### Table 4 The results of univariate and multivariate logistic regression analysis

| Data                                      | Univariate analysis OR (95% CI) | P     | Multivariate analysis OR (95% CI) | P     |
|-------------------------------------------|---------------------------------|-------|----------------------------------|-------|
| Urea nitrogen (First day after surgery)  | 0.934 (0.838, 1.042)             | 0.221 |                                  |       |
| SOFA score (First day after surgery)      | 1.208 (1.024, 1.426)             | 0.025*|                                  |       |
| VIS (First day after surgery)             | 1.081 (1.024, 1.140)             | 0.005*|                                  |       |
| VIS (Pre-CRRT)                            | 1.096 (1.046, 1.148)             | <0.001*|                                 |       |
| SOFA score (24 h after CRRT)              | 1.919 (1.310, 2.810)             | 0.001*| 1.321 (1.001–1.744)              | 0.05  |
| VIS (24 h after CRRT)                     | 1.138 (1.068, 1.212)             | <0.001*| 1.096 (1.024, 1.173)             | 0.008*|
| Negative balance of blood volume (24 h after CRRT) | 0.166 (0.059, 0.465)             | 0.001*| 0.326 (0.059, 1.787)             | 0.326 |
| Bleeding                                  | 7.682 (2.570, 22.960)            | <0.001*| 10.826 (1.824, 64.257)           | 0.009*|
| Infection                                 | 9.000 (3.016, 26.855)            | <0.001*| 3.120 (0.581, 16.754)            | 0.184 |
| MODS                                      | 13.470 (48.709)                  | <0.001*| 2.200 (0.319, 15.193)            | 0.424 |
| Duration of MV                            | 1.002 (1.000, 1.004)             | 0.011*| 1.001 (0.999, 1.004)             | 0.298 |
| Interval time from AKI to CRRT            | 1.031 (0.944, 1.125)             | 0.05  |                                  |       |

*There is a statistically significant difference
In conclusion, the SOFA score and VIS 24 h after CRRT, as well as the incidence rate of complicated bleeding after operation are independent risk factors for in-hospital mortality in CS-AKI patients with CRRT, timely treatment of maintaining stable hemodynamics and active prevention and treatment of bleeding complication are expected to decrease the in-hospital mortality, and improve the prognosis of these patients.

Limitation

This study has several limitations. First, our sample size is relatively small, it is only a single-center study, larger-scale and multicenter clinical observational studies on CS-AKI patients with CRRT are needed to clarify the risk factors for in-hospital mortality. Second, we did not follow up these patients after discharge.

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1007/s10157-022-02274-1.

Funding

This work was supported by Nantong scientific program, Grant number: MS12021038

Declarations

Conflict of interest

The authors have declared that no conflict of interest exists.

Human rights

This study was conducted in accordance with the principles established by the 18th World Medical Assembly (Helsinki, 1964) and all subsequent amendments. All protocols were approved by our hospital’s institutional review board (IRB number: 2020-K046).

Informed consent

Every participant provided written informed consent, and agreed that personal medical information would be legally and reasonably used by our hospital. Moreover, their privacy will be fully protected.

Open Access

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Bell M, SWING, Granath F, et al. Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. Intensive Care Med. 2007;33(5):773–780.
2. Rosner MH, Okusa MD. Acute kidney injury associated with cardiac surgery. Clin J Am Soc Nephrol. 2006;1(1):19–32.
3. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Kdigo clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–138.
4. Gaudry S, Hajage D, Schortgen F, et al. Initiations strategies for renal-replacement therapy in the intensive care unit. N Engl J Med. 2016;375(2):122–33.
5. Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotrop score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234–8.
6. Ronco C, Chionh CY, Haapio M, et al. The cardio renal syndrome. Blood Purif. 2009;27(1):114–26.
7. Zhang YD, Dai HY, Xie HL, et al. The role of renal damage on cardiac remodeling in patients with diabetic nephropathy. Clin Nephrol. 2013;80(4):249–55.
8. Li SY, Yang WC, Chuang CL. Effect of early and intensive continuous venovenous hemofiltration on patients with cardiogenic shock and acute kidney injury after cardiac surgery. J Thorac Cardiovasc Surg. 2014;148(4):1628–33.
9. Bahar I, Akgul A, Ozatik MA, et al. Acute renal failure following open heart surgery: risk factors and prognosis. Perfusion. 2005;20(6):317–22.
10. Elahi M, Asopa S, Pfueger A, et al. Acute kidney injury following cardiac surgery: impact of early versus late haemofiltration on morbidity and mortality. Eur J Cardiothorac Surg. 2009;35(5):854–63.
11. Perez-Valdivieso J R, Monedero P, Vives M, et al. Cardiac-surgery associated acute kidney injury requiring renal replacement therapy. A Spanish retrospective case-cohort study. BMC Nephrol. 2009;10:27.
12. Han H, Wen Z, Wang J, et al. Prediction of short-term mortality with renal replacement therapy in patients with cardiac surgery-associated acute kidney injury. Front Cardiovasc Med. 2021;8:738947.
13. Aittokallio J, Uusalo P, Kallioinen M, et al. Markers of poor prognosis in patients requiring continuous renal replacement therapy after cardiac surgery. J Cardiothorac Vasc Anesth. 2020;34(12):3329–35.
14. Uusalo P, Hellman T, Järvisalo MJ. Mortality and associated risk factors in perioperative acute kidney injury treated with continuous renal replacement therapy. Perioper Med (Lond). 2021;10(1):57.
15. Sanchez-de-Toledo J, Perez-Ortiz A, Gil L, et al. Early initiation of renal replacement therapy in pediatric heart surgery is associated with lower mortality. Pediart Cardiol. 2016;37(4):623–628.
16. Hassinger AB, Wald EL, Goodman DM. Early postoperative fluid overload precedes acute kidney injury and is associated with higher morbidity in pediatric cardiac surgery patients. Pediart Crit Care Med. 2014;15(2):131–8.
17. Xu J, Shen B, Fang Y, et al. Postoperative fluid overload is a useful predictor of the short-term outcome of renal replacement therapy for acute kidney injury after cardiac surgery. Medicine (Baltimore). 2015;94(33):e31360.
18. Tripathi S, Pande S, Malhotra P, et al. Optimal timing of renal replacement therapy for favourable outcome in patients of acute renal failure following cardiac surgery. Indian J Thorac Cardiovasc Surg. 2020;36(2):127–33.
19. Li B, Chen QL, Yao BC, et al. Risk factors of continuous renal replacement therapy following total aortic arch replacement under moderate hypothermia. Ann Transl Med. 2021;9(18):1448.
20. Liu C, Zhang HT, Yue LJ, et al. Risk factors for mortality in patients undergoing continuous renal replacement therapy after cardiac surgery. BMC Cardiovasc Disord. 2021;21(1):509.
21. Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care. 1996;22(7):707–10.

22. Ceriani R, Mazzoni M, Bortone F, et al. Application of the sequential organ failure assessment score to cardiac surgical patients. Chest. 2003;123(4):1229–39.

23. Pistolesi V, Di Napoli A, Fiaccadori E, et al. Severe acute kidney injury following cardiac surgery: short-term outcomes in patients undergoing continuous renal replacement therapy (CRRT). J Nephrol. 2016;29(2):229–239.

24. Yamazaki Y, Oba K, Matsui Y, et al. Vasoactive-inotrophic score as a predictor of morbidity and mortality in adults after cardiac surgery with cardiopulmonary bypass. J Anesth. 2018;32(2):167–73.

25. Sanil Y, Aggarwal S. Vasoactive-inotrophic score after pediatric heart transplant: a marker of adverse outcome. Pediatr Transpl. 2013;17(6):567–72.

26. Boss K, Jahn M, Wendt D, et al. Extracorporeal cytokine adsorption: significant reduction of catecholamine requirement in patients with AKI and septic shock after cardiac surgery. PLoS ONE. 2021;16(2):e0246299.

27. Koška A, Kirwan CJ, Kowalik MM, et al. Filter life span in postoperative cardiovascular surgery patients requiring continuous renal replacement therapy, using a post dilution regional citrate anticoagulation continuous hemofiltration circuit. Cardiol J. 2022;29(1):53–61.

28. Kim IY, Kim JH, Lee DW, et al. Fluid overload and survival in critically ill patients with acute kidney injury receiving continuous renal replacement therapy. PLoS ONE. 2017;12(2):e0172137.

29. Li XM, Liu C, Mao Z, et al. Timing of renal replacement therapy initiation for acute kidney injury in critically ill patients: a systematic review of randomized clinical trials with meta-analysis and trial sequential analysis. Crit Care. 2021;25(1):15.

30. Augoustides JG, Pochettino A, Ochroch EA, et al. Renal dysfunction after thoracic aortic surgery requiring deep hypothermic circulatory arrest: definition, incidence, and clinical predictors. J Cardiothorac Vasc Anesth. 2006;20(5):673–7.

31. Crescenzi G, Torracca L, Pierri MD, et al. “Early” and “late” timing for renal replacement therapy in acute kidney injury after cardiac surgery: a prospective, interventionanal, controlled, single-centre trial. Interact Cardiovasc Thorac Surg. 2015;20(5):616–21.

32. Elahi MM, Lim MY, Joseph RN, et al. Early hemofiltration improves survival in post-cardiomyotomy patients with acute renal failure. Eur J Cardiothorac Surg. 2004;26(5):1027–31.

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.